A phase III trial of ALN-AS1 in acute hepatic porphyria patients
Phase of Trial: Phase III
Latest Information Update: 03 Dec 2016
At a glance
- Drugs Givosiran (Primary)
- Indications Acute intermittent porphyria; Liver disorders; Porphyria
- Focus Therapeutic Use
- 03 Dec 2016 According to an Alnylam Pharmaceuticals media release, company plans to initiate this study in late 2017.
- 06 May 2016 New trial record
- 02 May 2016 Alnylam Pharmaceuticals plans to initiate this trial in 2017 if the phase I trial results are positive, according to a company media release.